Skip to main content
. Author manuscript; available in PMC: 2021 Dec 1.
Published in final edited form as: Adv Drug Deliv Rev. 2020 Jun 21;167:121–134. doi: 10.1016/j.addr.2020.06.012

Table 1.

NIR fluorescence imaging of antibodies.

Application (Target) Contrast agent Tracking time Animal model Ref
Trastuzumab, bevacizumab, Trastuzumab emtansine IRDye800CW, Alexa Fluor 680 4-17 d Xenograft tumor mice [56]
Cetuximab IRDye800CW 1 d Xenograft tumor mice [57]
Cetuximab, bevacizumab IRDye800CW 3 d Xenograft tumor mice [58]
Bevacizumab, trastuzumab IRDye800CW 4 d Xenograft tumor mice [59]
MPDL3280A (PD-L1) IRDye800CW 3-5 d Xenograft tumor mice [60]
Cys-diabody A2 (PSCA) sCy5 2-4 h Xenograft tumor mice [61]
Atezolizumab (PD-L1) ErNPs 3 d Syngeneic and Xenograft tumor mice [62]